Artixio

Pharmaceutical Regulatory Consultant in Mexico

 Helping pharma companies in Mexico with product approvals, compliance support, and regulatory consulting tailored to local needs. COFEPRIS-Focused Regulatory Support for Pharmaceutical Products. in Mexico

Regulatory Affairs

Product Registration

IND (Investigational New Drug)

NDA (New Drug Application)

Technical Writing

Regulatory Strategy

Digital Marketing

Market Access

Regulatory Operations

Our Pharmaceutical Regulatory Services in Mexico

Getting a product approved in Mexico means knowing how COFEPRIS really works—not just what the rules say, but how the process actually plays out. At Artixio, we help companies deal with that reality. Some come to us early, before filing anything. Others reach out after things have stalled or hit unexpected roadblocks. Either way, we get involved, figure out what’s needed, and help move things forward.

We work on all kinds of submissions—new product registrations, renewals, labeling updates, and safety-related changes. We also help companies coordinate with local license holders and ensure documents meet COFEPRIS expectations in both format and language. The goal isn’t just to get things filed—it’s to get them through.

Artixio’s Approach

Product Development → Approval → Commercialization

Phase Our Role
Product Development Assess COFEPRIS requirements early, provide regulatory feasibility input
Approval Handle end-to-end submission, coordination, and approval process
Commercialization Support post-approval compliance, renewals, and market access needs

COFEPRIS Process for Pharmaceutical Products

Stage What Artixio Does
Pre-Submission Review formulation & documentation, identify gaps, prepare regulatory roadmap
Submission Compile and submit dossier in required formats (Module I–V as per CTD), coordinate with COFEPRIS
Post-Submission Track progress, respond to information requests, support during technical evaluations

Product Types We Support

Why Work with Artixio for Pharma Solutions in Mexico?

Know how COFEPRIS works — not just on paper
Understand Spanish doc formatting and authority feedback
Experts in NCEs, Generics, 505(b)(2), and complex drugs
We stay involved after submission, not just during
Help fix delays, missing info, or stalled approvals
Used to working with global teams entering LATAM
Support across Rx, generics, OTC, and combos

FAQs

1. How long does it take to get a pharmaceutical product approved by COFEPRIS?
Approval timelines vary by product type. On average, generic drug approvals can take 4–8 months, while new molecules may take longer depending on dossier completeness and regulatory pathway.
Yes. COFEPRIS requires a local legal representative (holder) for marketing authorization. Artixio offers local representation services to support foreign manufacturers.
Start with a product classification check and regulatory pathway mapping. Artixio helps you assess COFEPRIS requirements based on your product type and global status.
Mexico doesn’t use the same regulatory term, but we assess whether your data package qualifies for simplified approval under COFEPRIS pathways.
Yes. If you appoint us or our local partner as your registration holder, we manage all COFEPRIS interactions on your behalf.

Regulatory Expertise Across
Multiple Countries

India
Vietnam
Mexico​
Vietnam
United States
Brazil
Europe
Malaysia
Taiwan
China
Thailand
Philippines

Industries we serve

Pharmaceuticals

Cosmetics

Nutrition

Medtech

Biologics

Veterinary

Insights from Artixio - Tips & Articles

CDSCO Medical Device Approval Cost & Fee Structure

CDSCO Medical Device Approval

Central Drug Standard Control Organization (CDSCO) is the regulatory authority that regulates Medical Devices...

July 29, 2025
Computer Software Assurance(CSA) In Pharma & Medical Industry

Computer Software Assurance(CSA) In

Under 21 CFR part 11, it is required to validate the electronic systems that...

July 28, 2025
In Vitro Diagnostics: Meaning, Types And Benefits

In Vitro Diagnostics: Meaning,

The term “in vitro” is a Latin word that means “in glass”. Thus, from...

June 20, 2025